- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mi | Glucotrack, Inc.: Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions | 1 | GlobeNewswire (USA) | ||
| 28.05. | Glucotrack appoints new board member with diabetes tech expertise | 1 | Investing.com | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 28.05. | Glucotrack, Inc.: Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD | 14 | GlobeNewswire (USA) | ||
| 20.05. | Glucotrack, Inc.: Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development | 1 | GlobeNewswire (USA) | ||
| 20.05. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Glucotrack GAAP EPS of -$0.67 | 1 | Seeking Alpha | ||
| 14.05. | Glucotrack, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 392 | GlobeNewswire (Europe) | On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device... ► Artikel lesen | |
| 13.05. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.05. | Glucotrack, Inc.: Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor | 226 | GlobeNewswire (Europe) | RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization... ► Artikel lesen | |
| 16.04. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.04. | Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe | 1 | MassDevice | ||
| 03.04. | Glucotrack, Inc.: Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor | 1 | GlobeNewswire (USA) | ||
| 31.03. | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | GlucoTrack, Inc.: Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | 71 | GlobeNewswire (Europe) | Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption... ► Artikel lesen | |
| 31.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | GCTK-Aktie stürzt | 4 | Investing.com Deutsch | ||
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Glucotrack, Inc.: Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 65,05 | -3,49 % | Eckert&Ziegler-Aktie leicht im Plus (62,55 €) | Der Anteilsschein von Eckert&Ziegler notiert am Montag etwas fester. Der jüngste Kurs betrug 62,55 Euro. Freuen können sich gegenwärtig die Aktionäre von Eckert&Ziegler: Die Aktie weist gegenwärtig... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,111 | 0,00 % | Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.... ► Artikel lesen | |
| SYNLAB | 12,640 | -0,55 % | Eurofins Scientific: Eurofins Announces the Successful Closing of Its Acquisition of SYNLAB's Clinical Diagnostics Operations in Spain | Regulatory News:
Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,040 | +0,50 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
| PING AN HEALTHCARE | 0,755 | 0,00 % | PA GOODDOCTOR (01833): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | ||
| UNIDOC HEALTH | 0,164 | -1,92 % | UniDoc Health Corp.: UniDoc Provides Update on Marketing Engagement | VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 3,040 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,012 | -16,44 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,274 | +3,01 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
| CYTOSORBENTS | 0,884 | -4,54 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| EMPOWER CLINICS | - | - | Empower Clinics Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| QUIDELORTHO | 25,400 | -2,31 % | Quidel auf der Jefferies-Konferenz: Strategische Neuausrichtung und Wachstumspläne |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,77 % bei einem Aktienkurs von 0,141 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.